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INTRODUCTION 
Streptococci have an important position in clinical medicine as human 
pathogens. Among them Group A Streptococci have had a special place as a 
causative agent of important clinical disease recently. Other members of this 
family are now coming to light as human pathogens and Group B Streptococci 
(GBS) have emerged as important pathogens within the last few decades. 
The GBS are known to cause a wide variety of infections in adults, but 
clinical interest in these bacteria mainly relates to their ability to cause serious 
neonatal illnesses especially meningitis and sepsis. In developed countries these 
organisms are the leading cause of neonatal sepsis and meningitis with a case 
fatality rate of 40 -80 %. The reason for this is not clear.  
Streptococcus agalactiae is the only species that carries the Group  B 
antigen. This organism was initially recognized as a cause of puerperal sepsis. 
Although this disease is now relatively uncommon,  S. agalactiae  has become 
better known as an important cause of septicaemia, pneumonia and meningitis 
in newborn children as well as a cause of serious disease in adults.  
Group B Streptococci are Gram-positive cocci (0.6 to 1.2 micrometre 
size) that form short chains in clinical specimens and longer chains in culture; 
features that make them indistinguishable on Gram stain from Streptococcus 
pyogenes. They grow well on nutritionally enriched media and in contrast with 
  
the colonies of Streptococcus pyogenes, the colonies of Streptococcus 
agalactiae are buttery with a narrow zone of beta haemolysis. Some GBS 
strains (1 -2%) are non-haemolytic, although their prevalence may be 
underestimated because non-haemolytic  strains are not commonly screened for 
the group B antigen.  
Strains of  Streptococcus agalactiae can be characterised on the basis of 
three serologic markers.  
1. The B antigen or Group-specific Cell Wall Polysaccharide antigen. 
2. Type-specific Capsular Polysaccharide Antigen (Ia, Ia/c, Ib/c, II, IIc, 
II to Viii)  
3. The Surface Protein or c protein.  
 Any person can carry GBS, but few become sick from it. The 
bacterium lives in the lower genital tract or gastro-intestinal system along with 
many other bacteria that are harmless to most people. The bacterium causes 
illness primarily in pregnant women and their babies and occasionally in the 
elderly and in adults with other illnesses such as cancer and diabetes.    
 If a pregnant women carries the GBS bacterium in her vagina or 
rectum at the time of labor and delivery, there is a 1 in 100 chance that her baby 
will become sick from GBS infection. The risk rises to 4% if a pregnant woman 
carries the bacterium and also has certain risk factors. These risk factors 
  
include- 
● Pre-term delivery before 37 weeks gestation 
● Prolonged rupture of membranes (longer than 18 hrs without delivering 
the baby) 
● Fever (100.40F or higher) during labour  
 Other risk factors include having a previous pregnancy resulting in a 
GBS- infected baby or having a urinary tract infection caused by GBS.  
 Babies who become sick with GBS infection take the bacterium into their 
bodies by ingesting GBS-containing amniotic or vaginal fluids during labor and 
delivery. 
 There are two forms of GBS infection in infants - Early-onset and Late-
onset. Babies with Early-onset infection develop symptoms within seven days 
of birth; most commonly with in the first day of life. Babies with a late-onset 
infection develop symptoms between seven days and 3 months of age.  
 About 80% of all GBS infections in newborns are Early-onset infections. 
Early-onset infections are almost always transmitted from mother to baby 
around the time of delivery. Late-onset infections can be contracted at delivery 
or acquired after birth from contact with the mother or other people who are 
GBS carriers. Babies with an Early-onset infection suffer from one or more 
conditions like Pneumonia, Sepsis (Blood infection) and less commonly 
  
Meningitis. Babies with Late-onset infections usually have Sepsis or 
Meningitis. 
 In spite of treatment with antibiotics, about 5% of babies with GBS die. 
Preterm babies are more likely to die from the illness than are full term babies. 
Most babies who survive GBS go on to develop normally. However among 
these who develop meningitis, up to 5 % suffer lasting nuerologic damage that 
can include cerebral palsy, sight and hearing loss, mental retardation, learning 
disabilities and seizures.  
 According to the 2002 guidelines of the Centers for Disease Control and 
Prevention (CDC), United States of America, all pregnant women should be 
screened for GBS at 35-37 weeks of pregnancy. The health care provider is to 
take a swab from the vagina and rectum and send the sample to a laboratory for 
a culture to test for the presence of GBS. The results are usually available in 24-
48 hours. If a pregnant woman is found to carry GBS, she should be treated 
with intravenous antibiotics during labour and delivery. A recent CDC study 
showed that this approach may prevent nearly 90% of Early-onset GBS 
infections. Taking oral antibiotics prior to labour   is not recommended as it is 
not effective in preventing GBS infection in the newborn. 
  The vaccination of women of child-bearing age and the provision 
of protection by placental transfers of specific antibody appears to be an ideal 
  
solution for the prevention of neonatal GBS sepsis. Vaccine trials in pregnant 
women would also be ethically difficult. As GBS disease is still a relatively rare 
event, large sample sizes would be needed to show an effect on neonatal sepsis 
rate.  
  In addition to potentially reducing neonatal GBS disease, 
vaccination could also lead to reductions in maternal GBS urinary tract 
infection and chorio-amnionitis and could potentially prevent preterm birth. 
Also, if   vaccination were a reality, the complications associated with  intra-
partum  antibiotic prophylaxis such as maternal anaphylaxis, antibiotic 
resistance and changes in neonatal sepsis rates would no longer present the 
same potential problems.        
AIMS OF THE STUDY  
 
 
 
1. To find out the prevalence of Group B Streptococci colonization in 
pregnant women at the time of admission and in their neonates. 
 
2. To find out the association of maternal colonization with Group B 
Streptococci  in pregnancy and maternal complications like 
Premature Rupture  of  Membranes (PROM), Preterm labor, 
Maternal fever, Puerperal sepsis.    
 
3. To correlate the association of swab positivity of Group B  
        Streptococci  in neonates and neonatal complications like  
  sepsis, pneumonia and  meningitis. 
REVIEW OF LITERATURE 
 
 Group B Streptococci is an important cause of neonatal infection in 
the Western Hemisphere. The recognition that the maternal colonization 
with the organism is a key factor in the occurrence of GBS associated 
neonatal morbidity and mortality was a milestone in the history of perinatal 
health1. A nation-wide change in health practices helped diminish mortality 
and morbidity associated with the disease. In India, however, the spectrum 
of GBS disease remains a largely under-recognized problem.   
 Puerperal sepsis has been described for centuries and ancient Indian 
texts in 1500 BC have recorded that good hygiene leads to a reduction in 
perinatal disease2. In 1879 Louis Pasteur identified Streptococcus as the 
causative organism for puerperal sepsis 3. Since the early 1930’s when 
Rebecca Lancefield proposed a grouping system for hemolytic Streptococci, 
Group A Streptococcus – Streptococcus pyogenes was widely acknowledged 
as the major pathogen associated with puerperal sepsis4. GBS was initially 
thought to be a commensal until 1937, when Fry reported 7 cases of GBS- 
associated puerperal fever with 3 deaths 5.  
 
        There is a spectrum of maternal and fetal GBS infections ranging from 
asymptomatic colonization to sepsis. Streptococcus agalactiae has been 
implicated in adverse pregnancy outcomes, including preterm labor, 
prematurely ruptured membranes, clinical and sub-clinical chorioamnionitis, 
and fetal and neonatal infections. The bacterium can also cause bactriuria, 
pyelonephritis, and postpartum metritis. Barbosa-Cesnik et al. 2003 have 
reported postpartum maternal osteomyelitis 6 and Berkowitz and McCaffrey, 
1990 have reported mastitis by GBS 7. 
  A higher prevalence has been found in younger women. . GBS 
is not considered a sexually transmitted infection and treatment of partners 
does not prevent re-colonisation of treated women. Throughout pregnancy 
colonization can be transient, intermittent or chronic 8.  
 
GBS SEROTYPES AND PATHOGENESIS  
 There are 9 antigenically distinct serotypes based on their capsular 
polysaccharide structure (types Ia, Ib, II-VII) identified to date. In the United 
States and Western Europe, types Ia, II and III accounted for 85 per cent of 
the isolates from infants 9,10. Recent studies in the US have demonstrated 
that Serotypes Ia, III and V (in descending frequency) accounted for 78 – 87 
per cent of early-onset (less than seven days after birth) invasive disease in 
newborn infants and parturient women 11,12. Late-onset GBS disease in 
infants 7 -90 days of age is dominated by serotype III, followed by serotypes 
Ia and V 12.  
 Studies from India show a variable distribution of serotypes. But the 
most common isolates belong to types III, II and Ib 13,14, 15. 
 The most important risk factor for early-onset GBS infection in the 
neonate in the presence of the organism in the maternal genitourinary tract at 
the time of delivery. Ascending bacteria from the maternal genital tract 
reach the amniotic fluid, usually after rupture of the amniotic membranes 1, 
16. Alternatively the newborn can come into contact with GBS during 
passage through the birth canal. When the foetus aspirates contaminated 
amniotic fluid, GBS reach the lower respiratory tract and damage pulmonary 
epithelial cells, resulting in pneumonia and respiratory distress usually 
within the first few hours after birth. Severe GBS sepsis occurs with 
intravascular invasion of bacteria and failure of the host to eliminate the 
pathogen 17, 18. Ascending infection can also occur through intact 
chorioamniotic membranes, with subsequent events occurring in utero, 
resulting in still births or death within hours after birth 16. The pathogenesis 
in late-onset disease is less clear. Horizontal transmission plays a major role, 
such as by close contact with the mother, breast-feeding and nosocomial 
transmission.  
 The polysaccharide capsule is the most important virulence factor 18. 
However, the role of surface localized GBS proteins in pathogenesis and 
protection is under intensive investigation 18. The presence of maternal 
serum antibodies to specific capsular polysaccharides of GBS serotypes 
appears to be protective against acquisition of neonatal GBS disease as 
colonized pregnant women with high levels of serum antibodies were less 
likely to have neonates with invasive GBS infection 19, 20. Moreover, infected 
infants had low levels of specific antibody to the infective serotype 21.  
 
PREVALENCE OF GROUP B STREPTOCOCCI 
During the 1970’s and 1980’s GBS emerged as a major pathogen in 
the United States and Western Europe with reported mortality rate of 15% - 
50 % 22, 23. In US 10-30% pregnant women are asymptomatic carriers of 
GBS in the genital and gastrointestinal tract at the time of delivery. The 
prevalence of GBS colonization in pregnancy is variable 24 . 
 Boyer KM, Gadzala et al ( 1982 ) reported that women who had 
positive GBS cultures between 26 and 28 weeks gestation only 65% 
remained colonized at term while 8% of those with negative prenatal 
cultures were positive for GBS at term 25. Treatment of these colonized 
mothers succeeded in temporarily eradicating the organism, but most of the 
women were recolonised within 6 weeks. At birth 50 – 65% of infants who 
are born to colonized mothers have positive GBS cultures from mucus 
membranes and   skin26. Approximately 98% of colonized newborn remain 
healthy. But 1–2% had invasive GBS infection. The overall incidence of 
neonatal GBS infection was approximately 2/1000 live births in United 
States prior to the introduction of intrapartum prophylaxis 23 
 Scrag and associates (2002 – 2003) reported a colonization rate of 20 
– 30% in a nation wide cohort sampled at a mean of 35 weeks 27 .  
El-Kersh TA, Al-Nuaim LA  et al  (2002 ) studied the carrier state   of 
GBS in Saudi females during 3rd trimester of pregnancy . This study 
included 217 pregnant women and documented a GBS colonization rate of 
27.6%.  Additionally, 50% of GBS colonized mothers vertically transmitted 
the organism to their newborns 28. 
Orrett FA. et al. analyzed 201 third trimester pregnant women of  
Trinidad and Tobago, West Indies. The prevalence of vaginal and rectal 
GBS colonization was 32.9%. GBS were isolated more frequently from 
women aged more than 24 years (36.6%) than those younger than 24 years 
(26.9%). Colonization rates were significantly greater among multigravid 
women than primigravid women.        
Dillon HC Jr, Gray E, et al (1982) did a longitudinal prospective study 
of carriage of GBS during pregnancy in 2,500 women over a three-year 
period. Carriage was documented in 18% of the women by anorectal culture, 
in 4 % by vaginal culture, and in 13 % by simultaneously obtained anorectal 
and vaginal cultures (Overall carriage rate, 35%). The intestinal tract 
appeared to be a primary reservoir for colonization in pregnant women 29.  
Terry RR Kelly FW. et al, (1999) did a study on 608 pregnant women 
between 1995 and 1997 to consider a number of possible risk factors for 
GBS. 14.0% of the study subjects were found to be colonized with GBS. 
White non-Hispanic women had a GBS colonization prevalence of 13.6%; 
for all others, prevalence was 18.7%. No statistically significant differences 
were found in regard to age, weight, number of prenatal visits income level, 
marital status, history of drug use, or parity. This study identified smoking as 
a possible risk factor for GBS infection with the GBS colonization rate for 
smokers was 33.1% versus 16.4% for nonsmokers. The authors concluded 
that routine screening for GBS infection during pregnancy may be beneficial 
because no strong risk factors for colonization exist 30.  
 Eren A, Kucukercan M, et al. (2005) studied 500 Turkish pregnant 
women and their newborn infants by collecting vaginal and rectal swabs 
from mothers, and umbilical and throat swabs from their infants. Maternal 
and infant colonization rates were found to be 9.2 % and 1.6 %, respectively. 
Vertical transmission rate was 15.2 %. Although invasive serotypes were 
predominant, the rarity of GBS disease in their study was thought to be due 
to low rates of maternal carriage or to their possessing protective levels of 
GBS- specific IgG antibody in their sera 31.  
 Gerard P, Verghote–D’Hulst M, et al did an epidemiological study 
and controlled trial of prophylactic treatment of the newborn. Colonization 
with GBS of the genital tract was studied in 1115 women during the last 
trimester of pregnancy. 6.82 % of women were found to harbour this 
bacterium. It was also more frequent in primigravidae. Rupture of the 
amniotic membranes for more than 24 hours was more often associated with 
GBS carriage by the mother. 42.6% of the infants born to GBS positive 
mothers were colonized at birth. The study also indicated that immediate 
therapy with penicillin of infants of GBS positive mothers has no definite 
advantage upon delayed treatment 32.  
 Schrag SJ, Zell ER et al in their  multistate retrospective cohort study 
they compared the effectiveness of the screening and risk-based approaches 
in preventing early-onset GBS disease in a sample of 629, 912 live births in 
1998 and 1999. Antenatal screening was documented for 52 percent of the 
mothers. The risk of early-onset disease was significantly lower among the 
infants of screened women than among those in the risk-based group. So 
routine screening for GBS prevents more cases of early-onset disease than 
the risk-based approach 33, 34, 35, 36, 37.  
 
Al-Sweih N,  Maiyegun S et al (2004) Kuwait University, studied the 
prevalence of GBS in Kuwait population. Anal, vaginal and combined anal 
and vaginal specimens were obtained from pregnant women at 35-37 weeks 
of gestation.  The combined vaginal and anal specimens were positive for 
GBS in 6.4 % of women. 38. 
  
PREVALENCE OF GROUP B STREPTOCOCCI 
Year of Study  Population 
studied  
Sample Size  Maternal 
Prevalence  
El-Kersh TA, Al-Nuaim 
LA  et al (2002 ) 
Saudi 
Arabia  
217 27.6  %  
Orrett FA. et al. (2004) West 
Indies  
201 32.9 % 
Dillon HC Jr, Gray E, et al 
(1982)  
USA  2500 35 %  
Terry RR, Kelly FW. et al, 
(1999) 
USA 608 14 % 
Eren A, Kucukercan M, et 
al. (2005)  
Turkey  500 9.20% 
Gerard P, Verghote–
D’Hulst M, et al (1979 ) 
Belgium  1115 6.82 % 
Al-Sweih N,  Maiyegun S Kuwait  110 6.4 % 
et al  (2004) 
 
 
 
STUDIES IN INDIA 
          Epidemiological studies in India have shown lower colonization and 
infection rates in general 13, 39, 40, 41.The reason is not known or the problem 
has not been adequately studied. There are only a few reports available 
however on closer analysis. 
 Stoll BJ, Schuchat A. (1998) reported that with the use of adequate 
culture techniques and microbiological media some of the GBS colonization 
rates reported from India and other developing countries are similar to those 
reported in United States 39.  
  Kulkarni AA, Pawar SG,  et al, Maharashtra studied the prevalence of 
GBS colonization and its risk factors in 317 pregnant women at the time of 
labour and in their neonates in 1998-1999. The GBS colonization rate in 
pregnant women at labour and in neonates was 2.52% and 1.26% 
respectively  with a frequency of transmission of 50%.  Only one risk factor 
has been seen in two GBS colonized mothers (i.e. in one case premature 
delivery and in the other case premature rupture of membranes) to be 
associated with GBS transmission . All isolates were sensitive to Ampicillin, 
Erythromycin and Penicillin followed by Chloramphenicol 66.6% (12/18). 
All isolates were resistant to Gentamicin, followed by Tetracycline (17/18) 
94.4%, and Kanamycin (16/18) 88.8% 42.    
    
Mhaskarrita, Sathyan Sharad et al (2005) St. John’s Medical College 
Hospital Bangalore had done a Selective risk factor based screening of 
pregnant women for GBS colonization. A retrospective analysis was done 
for the occurrence of GBS colonization among 741 pregnant women who 
were at risk i.e. they had at least one of the following risk factors namely-
prolonged rupture of membranes (>18 hours), preterm labor (<37 weeks), 
intrapartum fever, vaginal discharge, and previous baby with GBS infection, 
Vaginal swab and urine cultures indicated GBS. The occurrence of neonatal 
GBS infection was also studied. 
 The occurrence of GBS colonization was 1.62% and neonatal GBS 
infection was 0.53 per 1000 live births. 43,44,45, 46 . 
 Goyal R, Singh NP et al, GBS was examined in 304 pregnant women 
in Delhi, [2004]. Vaginal specimens were collected and examined for GBS. 
GBS was isolated from only 4 women (1.3%). It is suggested that GBS 
infection is not a problem in this population, and mass screening for GBS 
during pregnancy is not needed 47. 
     Dalal BS, Lahiri A et al  (1998) did a study on 507 pregnant Indian 
women; 12 per cent were reported to have GBS isolated from the throat and 
vagina, and 10 per cent had positive vaginal cultures alone 48.  
  
Chaudhary U, Sabherwal U et al   have reported colonization rates of 
5  to 6 per cent, but no selective broth media were used in these cases 13. 
 
PREVALENCE OF GROUP B  STREPTOCOCCI  IN INDIA 
   
Year of Study  Population studied  Sample 
Size  
Maternal 
Prevalence 
Kulkarni AA, Pawar 
SG,  et al  (2001) 
Govt.Medical College 
Maharashtra Miraj  
317 2.52 % 
Mhaskarrita et al 
(2005) 
St. John’s Medical 
College, Bangalore  
741 1.62 % 
Goyal R, Singh NP 
(2004) 
Guru Tegh  Bahadur 
Hospital,  Delhi  
304 1.3 % 
 
Jamie WE, Edwards RK et al (2004 ) performed a prospective cohort 
study to determine  whether the rates of recovery of Group B Streptococci 
from vaginal and perianal cultures and combined vaginal and rectal cultures 
are equivalent. 36% had a positive culture from at least 1 site. A significant 
finding was that the detection rate of Group B Streptococci from combined 
vaginal-perianal specimens is not significantly different from the detection 
rate from vaginal-rectal specimens.  The conclusion was that pregnant 
women need not be subjected to the discomfort of collection of a rectal 
specimen 49,50,51.  
 
GROUP B STREPTOCOCCAL INFECTION IN NEONATES 
It is estimated that about half of all babies born to women carrying 
GBS will themselves be colonized with GBS. However, the vast majority of 
these infants will not develop symptomatic GBS infection. A nation-wide 
study involving active surveillance of infants younger than 90 days showed 
377 cases of confirmed early-onset GBS neonatal sepsis  out of a total 
population of 794, 037 live births. It was calculated that the risk of early-
onset neonatal sepsis developing as a result of being colonized is about 5   
per 1000 52.  
 Recent evidence has suggested that the incidence of culture-proven 
GBS neonatal sepsis is likely to underestimate the true incidence of this 
infection in neonates. Data collected prospectively  in one centre in the UK 
for over a year for 413 neonates  who underwent a septic screen in the first 
72h after birth have suggested that the true incidence of early-onset neonatal 
GBS sepsis may be  as high as 3.6 per  1000 live  births 53. This was based 
on the presence of GBS colonization and symptomatic neonatal sepsis 
without isolation of any organism from a usually sterile site such as blood or 
CSF. 
 In the US, the incidence of culture-confirmed, early-onset GBS 
neonatal sepsis was 2-3 cases per 1000 live births in the early 1980 54. 
Following the introduction of a national screening and treatment programme 
advocated by the centers for disease control and prevention, the incidence of 
confirmed GBS neonatal sepsis has fallen to 0.32 per 1000 live births which 
is the lowest ever recorded (Fig.1) 55, 56. In contrast, the rate of late-onset 
GBS sepsis has remained fairly constant at 3.35 per 1000 live births over 
this period, leading to the suggestion that nosocomial infection plays a large 
part in the etiology of late-onset disease 56.   
 NEONATAL MORBIDITY 
Two distinct clinical syndromes are recognized, early-and late onset 
disease. Early onset GBS disease occurs within the first 7 days of life, 
although most cases are evident in the first 24 h after birth. As can be 
demonstrated by serotyping GBS isolates from colonized mothers and 
infants, transmission of early-onset disease is vertical 25. Infection may be 
acquired by the intraammiotic route, or directly during passage through the 
birth canal. The initial presentation is respiratory distress in more than 80 
percent of neonates 57. Pneumonia and septicaemia are the most common 
manifestations and 5 to 10 percent neonates will also have meningitis. The 
incidence of early-onset disease is about 10 times higher in premature than 
in term neonates. Late-onset disease develops in infants after 7 days and up 
to 3 months of age, the median age of onset being 1 month. Transmission 
can be either horizontal (from other infected infants or health care workers) 
or vertical (from the mother due to close proximity). These infants almost 
always have an unremarkable early neonatal history, and later present with 
meningitis or sepsis Osteoarticular infections and cellutitis can also occur 58. 
The case fatality rate in the US has dramatically decreased over the last 3 
decades, from up to 50 per cent in the 1970s to 6 per cent in the early 1990s 
59.  
Currently most centers and countries have experienced a decline in 
early –onset neonatal sepsis to rates of less than 1 to 2 per 1000 live births. 
Most reports, however, indicate no change or variable increases in rates of 
non-GBS organisms, such as E. coli and other Enterobacteriaceae  60, 61, 62, 63. 
 There is evidence that the major association with current intrapartum 
antimicrobial prophylaxis has been an increase in non-GBS early–onset 
sepsis in preterm, low-birth weight neonates, and especially very-low-birth 
weight neonates 63, 64. Stoll and associates (2002) observed a marked 
reduction in Group B streptococcal sepsis in these preterm neonates; this 
was offset by an increase in E coli sepsis.  
    Late-onset neonatal GBS sepsis is less well understood. Cited rates 
vary from 0.5 to 2 cases per 1000 live births and account for about 50 
percent of GBS disease in newborns 65,66. The incidence of late-onset disease 
has remained stable despite widespread use of intrapartum antimicrobials, 
suggesting that GBS screening and chemoprophylaxis intervention may not 
affect late-onset disease. Lin and co-workers (2003) reported that preterm 
birth before 34 weeks was the major risk factor 66. Stoll BJ, Hansen N 
(2002) found that the late-onset sepsis was identified in a fourth of very-low-
birth weight newborns; there was a preponderance of gram-positive 
organisms, mainly coagulase-negative staphylococci.  
The most recent report from the CDC  2002  reports mortality rate of 
0.7 per 100,000 population 67. Case series from India also report high 
mortality. In a 1975 study where 8 cases of neonatal GBS infection were 
followed over a period of 18 months, 6 infants died within the first week of 
diagnosis 68. A more recent study published in 1999 reported 10 infants with 
GBS infection, of which 1 died on the second day of life. However, there is 
insufficient data presented to calculate the actual mortality rate 69.  
Kuruvilla KA, Thomas N et al (1999) The incidence of GBS 
bacteraemia was 0.17 per 1000 live births. Lethargy, respiratory distress and 
poor perfusion were the presenting features in eight symptomatic babies. 
Two babies had meningitis, three required ventilatory support and one died. 
There were no cases of late onset disease. The low incidence could be due to 
the low rate of colonisation and high prevalence of protective antibody in the 
mothers.  
 The estimated incidence of neonatal GBS infection in India can be 
calculated from Indian epidemiological data reporting maternal and infant 
GBS colonization rates as 10 and 5 per cent respectively. Since about 2 per 
cent of colonized neonates develop true infection, the attack rate of neonatal 
GBS infection in India may be calculated as approximately 1 per 1000 live 
births. Bearing in mind the above estimated attack rate and current Indian 
demographic data (midyear population count in the year 2001 was 
approximately 1027 million, and birth rate was 26 births per 1000 
population per year), the projected total number of GBS infection in 
newborn infants in India may be a s high as 26,700 cases per year 70.  
Strakova ,Motlova et al (2003) isolated GBS from 239 full-term and 
46 preterm newborns. They reported the incidence of Early onset disease 
due to GBS  in  Czech Republic is 0.7-1.0 per 1000 live births 71.  
NEONATAL PREVALENCE 
   
Year of Study  Population 
studied  
Sample Size  Maternal 
Prevalence  
Kuruvilla et al 1999 CMC Vellore   60119 
0.17/1000 live 
birth  
Kulkarni & pawar etal 
2001 
Govt.Medical 
College. Miraj   
317 1.26 % 
Mahskarrita etal 2005  
St.John’s Medical 
College 
Bangalore   
741 
0.53 / 1000 
live birth  
National Surveillance 
Study  
UK  568 
0.72 / 1000 
live birth  
Strakova & Motlova 
etal  2003  
Czech Republic  285 
0.96 / 1000 
live birth  
 
Klebanoff MA, Regan JA, and associates (1995) did a double-blind 
study to determine whether Erythromycin treatment of pregnant women 
colonized with GBS would reduce the occurrence of low birth weight. 
Erythromycin or placebo was given to pregnant women beginning during the 
third trimester and before 30 weeks and continuing for 10 weeks or until 35 
weeks 6 days of pregnancy.   Study concluded that treating pregnant women 
colonized with GBS with Erythromycin was not effective at prolonging 
gestation or reducing low birth weight 72.  
 
 Kurien Anil Kuruvilla, Swati Pillai etal  studied on  babies born in the 
Christian Medical College Hospital (CMCH), Vellore,(1995-1996) .Infants 
with clinical signs of sepsis or those who were born to mothers with 
potential risk factors for infection were screened for sepsis. Risk factors in 
the mother for EOS included prolonged rupture of membranes (PROM >24 
hours), maternal pyrexia, untreated urinary tract infection (UTI), 
chorioamnionitis, or multiple vaginal examinations.The incidence of 
neonatal bacterial sepsis is 9.8 per 1000 livebirths. E. Coli and Klebsiella 
were the most common organisms causing EOS and LOS. Enterococcus 
fecalis was also a major pathogen, both in EOS and LOS 73. 
 
OTHER ORGANISMS ASSOCIATED WITH GENITAL 
TRACT INFECTION 
Any infection can lead to preterm labour and premature rupture of 
membranes .Recently lower genital tract infections has been associated with 
preyerm labour .one of the important issue being highlighted is bacterial 
vaginosis .Bacterial vaginosis describes a polymicrobial alteration of vaginal 
flora resulting from overgrouth of the anaerobic bacteria and gardenella 
vaginalis than lactobacillus .The major bacterial vaginosis associated  
organisms are Gardenella vaginalis, anaerobic gram negative rods, 
Bacteroides, Peptostreptococcus, Mycoplasma hominis and Ureaplasma 
urealyticum. 
 PREVENTION STRATEGIES 
Lacking randomized trials, consensus opinions and guidelines on 
prevention strategies have been promulgated by the American College of 
Obstetricians and Gynecologists (2002) and the Centers for Disease Control 
and Prevention (2002). These guidelines advocate a culture –based screening 
approach to identify women who should receive intrapartum prophylaxis. 
This recommendation was derived from a multistate, retrospective cohort 
study of live births in 1998 and 1999 from the Active Bacterial 
Surveillance/Emerging Infections program network, which suggested that 
the culture-based approach was superior to a risk-based approach.  
 With the culture-based approach, women are screened for GBS 
colonization at 35 to 37 weeks, and intrapartum antimicrobials are given to 
rectovaginal carriers. Previous siblings with GBS invasive disease and prior 
identification of GBS bacteruria are also considered indications for 
prophylaxis. A risk – based approach is recommended for women with un-
known GBS culture results at the time of labor. 
 The choice of antimicrobials may be important in terms of allergic 
reaction; selection of resistant GBS strains; and emergence of other 
pathogens, including antimicrobial-resistant strains, as agents of neonatal 
sepsis. The centers for disease control and prevention recommendations 
specify penicillin as a first-line agent 66. Ampicillin is an acceptable 
alternative 73. For women with penicillin allergy, if the risk of anaphylaxis is 
low, cefazolin is recommended 74. If the risk of anaphylaxis is high, 
selection of a prophylactic agent is dependent on GBS susceptibility testing. 
Patients with isolates susceptible to clindamycin or erythromycin may be 
given either drug. Antimicrobial resistant strains require vancomycin 
prophylaxis. This treatment scheme is dependent on laboratory capability to 
perform susceptibility testing.  
 Importantly, there have been no randomized controlled trials 
comparing antenatal screening. In addition, there have been no randomized 
trials comparing the different screening strategies and whether prenatal GBS 
screening has a significant impact on overall neonatal sepsis. For these 
reasons, clinicians in other countries state that there is in sufficient evidence 
to recommended screening for GBS carriage 75,76,77. 
 Alternative prevention strategies have been described with limited 
evidence to recommend them. These include intramuscular benzathine 
penicillin G and chlorhexidine vaginal lavage 78. In another study, Haberland 
colleagues (2002) reported that intrapartum rapid PCR screening for GBS 
may be superior to current strategies; however, this must be proven effective 
in clinical trails 79. In GBS- Positive women, appropriate vaginal 
examinations or indicated intrauterine fetal monitoring should not be 
avoided as their avoidance could actually prolong labor and thus increase the 
risk of infection80.  
 Implementation of several protocols is associated with diminished 
GBS. There are, however, still major concerns about antimicrobial 
resistance, particularly among very-low birth weight neonates. Ongoing 
surveillance is necessary to monitor protocol efficacy for prevention of 
early-onset GBS sepsis as well as for any effects on maternal morbidity, 
overall neonatal sepsis, and resistant infections.  
VACCINATION 
  Some protection against serious neonatal infection is conferred by 
maternal antibodies. Indeed, Lin and colleagues (2001) have confirmed that 
the susceptibility to invasive GBS disease correlates with deficiency in 
maternal type-specific antibody levels 81. Baker and co-workers reported that 
maternal immunization to type III antigen produces antibody in about 60 
percent of women Monovalent tetanus toxoid conjugate vaccines are 
immunogenic for common GBS disease –associated serotypes 82,83,84. 
Paoletti and Modoff (2002) have reviewed the progress toward development 
of a multivalent vaccine 85.         
MATERIALS AND METHODS  
 
Women admitted to PSG Hospitals with labour pain, preterm labour, 
premature rupture of membranes were included in the study irrespective of 
gestational age, parity, or socioeconomic status. Two hundred women and 
their neonates were included in the study from February 2006 to February 
2007.   
 
METHODS  
Sample Collection  
 At the time of admission to the labour Room, two swabs were 
collected from all pregnant women who were admitted with labour pain, 
preterm labour, or premature rupture of membranes. Four swabs were 
collected from all neonates soon after birth.  
 Maternal Sample Collection  
 After obtaining the informed written consent, two swabs were 
collected from each mother-one from the vagina and the other from the 
rectum.     
Vaginal Sample Collection 
 One swab was collected from the lower vagina taken prior to first 
pelvic examination. No antiseptic preparation of the perineum or vulva was 
carried out before swabbing. Speculum was not used for culture collection. 
Rectal Swab Collection  
 A different swab was inserted through the anal sphincter and a sample 
was taken. 
Both the vaginal swab and the rectal swab were placed in selective broth 
medium and transported to the laboratory. 
Samples from Neonates  
 A total of four samples were collected from each newborn infant 
immediately after birth. Swabs were taken from the external ear, nose, throat 
and umbilical region. These swabs were transported to laboratory after 
placing the swabs in selecting broth medium. (Todd-Hewitt broth)  
Selective Broth Medium 
 The Selective Broth Medium we used in our study was Todd-Hewitt 
broth which was supplemented with Gentamycin-8 micrograms/ml and 
Nalidixic Acid-15 micrograms/ml. 
  Procedure for Processing the Clinical Specimen for culture of GBS  
1. The swab is inoculated into the Todd-Hewitt broth supplemented 
with Gentamycin-8 micrograms/ml and Nalidixic Acid-15 
micrograms/ml. 
2. Inoculated Todd-Hewitt broth was incubated for 24 hours at 37OC 
in ambient air 
3. The samples were then transferred to 5% Sheep's Blood Agar and 
incubated for a further 24  hours at 37OC.  
4. Plates were then examined for growth of Group B Streptococci. If 
no growth was found, the plates were incubated for an additional 
day and re-examined for growth of the organism. If no growth was 
found on the second examination, the plates were declared as 
negative.   
 
 Demonstration of Group B Streptococci. 
GBS – appearance in 5% sheep blood agar  
 The colony is usually gray, soft, shiny, convex, moist, regular and about 
1 mm in diameter and surrounded by a small hazy zone of beta haemolysis. 
Gram stain 
 Gram stain of pinpoint colonies is done to demonstrate the presence of 
Gram positive cocci arranged in short chains. 
Confirmation of GBS  
 GBS Growth was confirmed by CAMP Test. 
Antibiotic sensitivity 
 The isolates were tested for antibiotic sensitivity by disc diffusion 
method of Kirby-Bauer.   Antibiotics tested were Ampicillin, Erythromycin. 
Tetracycline, Chloramphenicol and Vancomycin. 
 
Post-Natal Follow-up 
 All mothers in the study were followed up during the period of 
admission, and by outpatient clinic visits after discharge, for a period of 45 
days for fever, urinary tract infection, and vaginal discharge. 
 Neonates were followed up during the period of admission, and by 
outpatient clinic visits after discharge, for a period of 90 days after delivery 
for late onset infections such as meningitis, sepsis and pneumonia. 
RESULTS AND ANALYSIS  
 
In our study samples were taken from two hundred women and their 
neonates who were admitted to the labour room in PSG Hospital from Feb 
2006 to Feb 2007. Maternal swabs were taken at the time of admission to the 
labour room, and  swabs from the neonates were taken after delivery. Both 
samples were cultured separately. All the samples were from singleton 
pregnancies.  
 
 Caesarean deliveries and those deliveries resulting in intra-uterine 
deaths were excluded from the study. Mothers and their babies were 
followed up for a total of ninety days after delivery for maternal and fetal 
complications of Group B Streptococcus infection. 
 
 
 
 
 
 
 MATERNAL AGE OF STUDY GROUP  
The age of the mothers included in the study were analyzed. 
Table 1 – SHOWING MATERNAL AGE OF STUDY POPULATION 
Age of Patients No. of cases Study group in percent 
< 19 yrs  12 6 % 
20 – 29 yrs  163 81.5 % 
> 30 yrs  25 12.5 %  
 
In our study, 81.5% of the patients were in the age group of 20 to 29 
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FIG 1 – SHOWING MATERNAL AGE OF STUDY POPULATION 
 
PARITY STATUS 
It was found that in our study 52 percent of women were primiparous and 48 
percent were multiparous 
Table 2 -TABLE SHOWING PARITY STATUS OF PATIENTS  
PARITY NUMBER OF CASES STUDY GROUP IN 
PERCENTAGE 
PRIMIPAROUS 104 52 % 
MULTIPAROUS 96 48  % 
 
Number of Cases
104
96
Primi
Multi
 
 
FIGURE 2 – PIE CHART SHOWING PARITY STATUS OF STUDY 
PATIENTS
SOCIOECONOMIC STATUS 
An analysis was done of the socio-economic status of the women enrolled in 
the study. The classification was based on the occupation of the husband.  
 
Table 3 – SHOWING SOCIO-ECONOMIC STATUS OF STUDY 
POPULATION 
Socioeconomic status  Percentage  
Higher Professionals and other 
professionals – Including those in 
managerial positions 
1 % 
Skilled Workers – Non manual  11 % 
Skilled Workers – Manual  14 % 
Semi –skilled workers  28 % 
Unskilled Workers  46 % 
It was found that the largest proportion of patients in the study belonged to 
the lower socio-economic group. 
Percentage 
1% 11%
14%
28%
46%
Higher Professionals
other professionals –
Including those in
managerial positions
Skilled Workers – Non
manual 
Skilled Workers –
Manual 
Semi –skilled workers 
 
FIGURE 3 – SHOWING SOCIO-ECONOMIC STATUS OF STUDY 
POPULATION 
 PREVALENCE OF GROUP B STREPTOCOCCI IN STUDY 
POPULATION  
Maternal Swabs positive for Group B Streptococci  
Maternal Swabs  
Positive for 
Group B 
Streptococci  
Negative for 
Group B 
Streptococci  
Total  
Number  4 196 200 
Percentage  2 98 100 
 
Table 4 – MATERNAL SWAB POSITIVITY FOR GROUP B Streptococci 
4 cases making up 2.0 % of the study population were found to be positive 
for group B Streptococcus 
Number 
4
196
Positive for Group B
Streptococci 
Negative for Group B
Streptococci 
 
 
FIGURE 4 - MATERNAL SWAB POSITIVITY FOR GROUP B 
Streptococci 
GBS – appearance in 5% sheep blood agar  
The colony is usually gray, soft, shiny, convex, moist, regular and 
about 1 mm in diameter and surrounded by a small hazy zone of beta 
haemolysis. 
 
 
 
 
 
 
FIG -GBS – APPEARANCE IN 5% SHEEP BLOOD 
AGAR  
GRAM STAIN 
Once the colonies were found, Gram stain of pinpoint colonies is done to 
demonstrate the presence of gram positive cocci arranged in short chains  
 
 
 
 
 
FIG – GRAM STAIN OF GROUP B STREPTOCOCCI 
 
Confirmation of GBS  
 GBS Growth was confirmed by CAMP Test. 
 
CAMP TEST 
 CAMP (Christie, Atkins and Munch-Peterson) test is used to identify 
Group B streptococci. CAMP substance is a peptide produced by group B 
Streptococci which acts synergistically with the β – hemolysis produced by 
some strains of Staphylococcus aureus enhancing the effect of haemolysis. 
 The test is performed by inoculating S.aureus strain as a straight line 
on the surface of the sheep blood agar. Known positive control (Group B 
Streptococci), known negative control (group A Streptococci) and test 
strains are also inoculated as a straight lines parallel to S.aureus streak line 
leaving 1 cm space. The plate is incubated aerobically at 37OC overnight in 
an environment of 5-10% CO2. Positive test is indicated by an arrow head 
zone of hemolysis near the S.aureus growth. Negative test is indicated by the 
absence of arrow head zone of hemolysis.  
 
 
FIG – CAMP TEST 
Antibiotic sensitivity 
After the growth has been confirmed, the isolates were tested for antibiotic 
sensitivity by disc diffusion method of Kirby- Bauer   
 In this method antibiotic sensitivity of the bacteria was determined by 
disc diffusion method. Standard suspensions of bacteria to be tested are 
inoculated on the surface of Mueller-Hinton agar plates. Filter paper discs 
containing specific concentration of antimicrobial agents are pressed on to 
the surface and incubated at 35OC overnight. After incubation, the zone of 
inhibition of growth of bacteria around each disc is measured and the 
susceptibility is determined.    
 Each antibiotics produces a specific zone size for each bacteria tested. 
Depending on the zone size, the bacteria are classified as follows.  
Sensitive (S)     :  Infection treatable with normal dosage of the antibiotic.  
Intermediate (I) :  Infection may respond to therapy with higher dosage. 
Resistant (R)     :  Unlikely to respond to the antibiotic at the usual dosage.   
 
 
FIG – DISC DIFFUSION TEST 
 
Like the Group A Streptococci, isolates of Group B Streptococci 
remain susceptible to penicillin G, the drug of choice for treatment of 
infections and for perinatal chemoprophylaxis of women who are vaginal 
carriers of Group B streptococci. Ampicillin, cefotaxime, ceftriaxone, 
cefezolin, and meropenem are also highly active, with most strains having 
minimal inhibitory concentrations (MICs) of < 0.06 µg/mL. Some Group B 
Streptococci demonstrate resistance to erythromycin and clindamycin.  All 
group B streptococcal strains tested to data have been susceptible to 
vancomycin.   
Isolates of  GBS obtained in our study was sensitive to 
Vancomycin, Erythromycin, Penicillin, Ciprofloxacin and Tetracycline 
and showed resistance to Amikacin and Gentamycin. 
BIRTH WEIGHT OF NEONATES 
The birth weight of the neonates born during the study was analyzed. 
Table 5 - SHOWS THE BIRTH WEIGHT OF THE NEONATES BORN 
DURING THE STUDY 
Birth weight No of New Born Percentage 
≤2.49 Kg 36 18 % 
2.5- 3.49 158 79 % 
≤3.5 Kg 6 3 % 
 
79% of the babies born during the study weighed between 2.50 and 3.49 
kilograms. 
Out of the 36 babies who weighed less than 2.49 kg,  7 babies were from 
preterm deliveries. 
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FIGURE 5 – SHOWING THE WEIGHT CATEGORIES OF 
NEONATES BORN DURING THE STUDY PERIOD. 
GENDER OF THE NEONATES 
An analysis was done of the genders of the neonates born to the study 
population.  
Table 6 – SHOWING NUMBER AND PERCENTAGE OF THE 
GENDER OF THE NEONATES 
Sex No of new Born Percentage 
Male 107 53.5 % 
Female 93 46.5 % 
 
It was found that males made up 53.5% of the neonates born during the 
study. 
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FIGURE 6 – SHOWING PERCENTAGE OF EACH GENDER IN 
NEONATES BORN DURING THE STUDY 
NEONATAL SWAB POSITIVE FOR GROUP B 
STREPTOCOCCI  
Neonatal Swabs  
Positive for 
Group B 
Streptococci  
Negative for 
Group B 
Streptococci  
Total  
Number  1 199 200 
Percentage  0.5 99.5 100 
 
Table 7 -NEONATAL SWAB POSITIVITY FOR GROUP B 
Streptococci 
One neonatal swab making up 0.5% of the study population was 
positive for Group B Streptococci. 
Number 
1
199
Positive for Group B
Streptococci 
Negative for Group B
Streptococci 
 
FIGURE 7 - NEONATAL SWAB POSITIVITY FOR GROUP B Streptococci 
 
CORRELATION BETWEEN MATERNAL AND 
NEONATAL SWAB RESULTS.  
 
Neonatal Swab 
Positive for 
Group B 
Streptococci  
Neonatal Swab 
Negative for 
Group B 
Streptococci 
Total  
Maternal Swab 
Positive for 
Group B 
Streptococci  
 
1 
 
3 
 
4 
Maternal Swab 
Negative for 
Group B 
Streptococci 
 
0 
 
196 
 
196 
Total  1 199 200 
Table 8– SHOWING CORRELATION BETWEEN MATERNAL AND NEONATAL 
SWAB RESULTS 
 It was found that one neonatal swab in the study was positive for 
Group B Streptococci, and the swab taken from the mother of this child was 
also positive for the bacterium.  
In another 3 cases, the maternal swab was found to be positive for Group B 
Streptococcus, while the swabs from the neonates born to those mothers 
were negative for the bacterium. 
 
Group B Streptococci Maternal Positivity and Maternal 
Outcome  
Maternal Swab Positivity for Group B Streptococci and Maternal 
Fever  
Group B 
Streptococci in 
Maternal Swab 
Maternal Fever 
present 
Maternal Fever 
Absent Total 
Present  0 4 4 
Absent  6 190 196 
Total  6 194 200 
 Table 9 – MATERNAL SWAB POSITIVITY AND MATERNAL 
FEVER 
 In the 4 cases that were positive for group B Streptococci in the 
vaginal swabs, maternal fever was found in none of cases.  
 It was also found that maternal fever was found in 6 of cases where 
maternal swabs were negative for group B streptococci.  
 
 It therefore appears that other organisms and possibly, other foci of 
infection, which were not tested for in the present study, are important 
causes of maternal fever in the peripartum period.  
MATERNAL SWAB POSITIVITY FOR GROUP B 
STREPTOCOCCI AND VAGINAL DISCHARGE  
Group B 
Streptococci in 
Maternal Swab 
Vaginal 
Discharge  
present 
Vaginal 
Discharge  
Absent 
Total 
Present  1 3 4 
Absent  3 193 196 
 
 Table 10 – MATERNAL SWAB POSITIVITY AND VAGINAL 
DISCHARGE 
Vaginal discharge was present in one case where maternal swabs were 
positive for group B streptococci and in three cases where maternal swabs 
were negative for Group B Streptococci  
 
 
MATERNAL SWAB POSITIVITY FOR GROUP B 
STREPTOCOCCI AND MATERNAL URINARY TRACT 
INFECTION  
 
Group B 
Streptococci in 
Maternal Swab 
Urinary Tract 
Infection 
present 
Urinary Tract 
Infection 
Absent 
Total 
Present  0 4 4 
Absent  8 188 196 
Total  8 192 200 
 
Table 11 – MATERNAL SWAB POSITIVITY AND MATERNAL 
URINARY TRACT INFECTION 
 
Maternal Urinary Tract Infection was absent in all cases who were positive 
for group B Streptococci and in 4 % percent of cases where maternal swabs 
were negative for Group B Streptococci.  
 
MATERNAL SWAB POSITIVITY FOR GROUP B 
STREPTOCOCCI AND PRETERM LABOUR  
Group B 
Streptococci in 
Maternal Swab 
Preterm Labour 
present 
Preterm 
Labour Absent 
Total 
Present  1 (0.5%) 3  (1.5%) 4( 2.0%) 
Absent  7 (3.5%) 189 (94.5%) 196 (93.0%) 
Total  8 (4.0%) 192 (96.0%) 200 (100.0%) 
 
Table 12– MATERNAL SWAB POSITIVITY AND PRETERM 
LABOUR 
 
Preterm Labour was present in  25 percent of cases where maternal swabs 
were positive for Group B Streptococci and in 3.5 % percent of cases where 
maternal swabs were negative for Group B Streptococci.  
 
 
MATERNAL SWAB POSITIVITY FOR GROUP B 
STREPTOCOCCI AND NEONATAL SEPSIS   
Group B 
Streptococci in 
Maternal Swab 
Neonatal Sepsis  
present 
Neonatal Sepsis  
Absent 
Total 
Present  1 (0.5%) 3 (1.5%) 4 (2.0%) 
Absent  4 (2.0%) 192 (96.0%) 196 (98.0%) 
Total  5(2.5%) 195 (97.5%) 200 (100.0%) 
 
Table 13 -  MATERNAL SWAB POSITIVITY AND NEONATAL 
SEPSIS 
Overall, Neonatal Sepsis was found in 2.5% of the total cases of the 
study. 
Neonatal Sepsis was present in 20% percent of cases where maternal 
swabs were positive for Group B Streptococci and in 1.5% percent of cases 
where maternal swabs were negative for Group B Streptococci. 
 
 MATERNAL SWAB POSITIVITY FOR GROUP B STREPTOCOCCI 
AND PREMATURE RUPTURE OF MEMBRANES   
 
Group B 
Streptococci in 
Maternal Swab 
Premature 
Rupture of 
Membranes 
Present 
Premature 
Rupture of 
Membranes 
Absent 
Total 
Present  1 (0.5%) 3 (1.5%) 4 (2.0%) 
Absent  20 (10.0%) 176 (88.0%) 196 (98.0%) 
Total  21 (10.5%) 179 (89.5%) 200 (100.0%) 
 
Table 14 -  MATERNAL SWAB POSITIVITY AND PREMATURE 
RUPTURE OF MEMBRANES 
The overall rate of Premature Rupture of Membranes in the study patients 
was 21%. Premature Rupture of membranes was present in 25% percent of 
cases where maternal swabs were positive for group B Streptococci and in 
10.2% percent of cases where maternal swabs were negative for Group B 
Streptococci. 
NEONATAL SWAB RESULTS AND OUTCOME  
 One Swab taken from a neonate was found to be positive for Group B 
Streptococci. The mother of this neonate was also positive by vaginal swab 
for Group B Streptococci, the pregnancy was associated with Premature 
Rupture of Membranes and the neonate was diagnosed with neonatal sepsis. 
After treatment, the neonate made a full recovery.  
 
 
PREVALENCE OF GROUP B STREPTOCOCCI AND ITS 
ASSOCIATION WITH MATERNAL AND NEONATAL 
COMPLICATIONS. 
 
1. Prevalence of Group B Streptococci in Maternal Samples - 2 % 
2. Incidence of Preterm Labour among the Study patients - 3.5 
% 
3. Association of Group B Streptococci in Maternal  
 Samples with Preterm Labour            - 25 
% 
4. Relative Risk of Group B Streptococci  
  Causing Preterm Labour         - 8.33 
5. Incidence of Premature Rupture of Membranes  
  Among the Study patients       - 10.2 
% 
6. Association of Group B Streptococci in Maternal  
  Samples with Premature Rupture of Membranes   – 25 
% 
7. Relative Risk of Group B Streptococci Causing   
  Premature Rupture of Membranes    - 
2.083  
8. Incidence of Neonatal Sepsis among the Study patients - 1.5 
% 
9. Association of Group B Streptococci in  
  Maternal Samples with Neonatal Sepsis   - 20 
% 
10. Relative Risk of Group B Streptococci Causing   
 Neonatal Sepsis         - 12.25 
  
DISCUSSION  
 
 The Group B Streptococci (GBS) are known to cause a wide variety of 
infections in adults, but clinical interest in these bacteria mainly relates to their 
ability to cause serious neonatal illness, especially meningitis and sepsis. In 
developed countries these organisms are the leading cause of neonatal sepsis 
and meningitis with a case fatality rate of 40 to 80%. 85. The reason for this is 
not clear. However, in developing countries like India, the problem has not been 
adequately studied and there are only a few reports available 86,87,88,89. In the 
present study most of the females were from lower socioeconomic group and in 
18 to 35 years of age group.  
 In our study of 200 women, we have found a prevalence of GBS 
colonization in mothers to be 2.0%. This is comparable with other studies 
conducted in India, such as those by Kulkarni et al, Mhaskarrita et al, and Singh 
et al, which have found a prevalence ranging from 1.3% to 2.5%. 42, 43, 44, 45, 46, 47  
 Studies conducted in other countries, however have prevalance rates to 
be higher, ranging from 6.4% to 35.0% 28, 29, 30, 31, 32, 33, 34, 38. The reason for this 
difference between studies conducted in India and other countries is not clear. 
 In adult women, GBS carriage in the genital tract, perineal skin and 
gastrointestinal tract is of great importance in view of its significance in GBS 
neonatal infection, whether asymptomatic mucous membrane colonization or 
  
symptomatic invasive infection (early onset septicemia, meningitis etc.)  In the 
present study we found that only one neonate was colonized by GBS. Thus an 
invasive attack rate was found to low. This might be due to passive 
immunization of newborns via transplacental transfer of type specific serum 
antibodies from their mothers. Also there was complete absence of GBS 
colonization in neonates of non colonized mothers, and this probably indicates 
that nosocomial infection of GBS was not a major problem in this hospital.  
 Considerable work has been done to determine the complications 
associated with GBS carriage. A number of factors are involved, like maternal 
urinary tract infection, premature or prolonged rupture of membranes, 
premature delivery, and peak intrapartum fever greater than 37.5OC. 
 Some workers give weightage to lack of type specific antibodies by 
neonates due to failure of transplacental transfer of these antibodies. This is 
responsible for GBS colonization, or in turn GBS disease in the newborn.  
 For better isolation of GBS from clinical material the use of transport 
medium has revealed the critical consideration. Several works tried different 
methods of transportation of clinical specimens from patients to the laboratory. 
In the present study we used Todd-Hewitt's broth as selective broth, and the 
samples were then cultured in Sheep Blood Agar.  
 
  
SEROTYPES AND FACTORS AFFECTING VIRULENCE 
The Group B β-hemolytic Streptococcus (S. agalactiae) contains a 
Lancefield-grouping antigen, a type-specific cell-surface polysaccharide and 
protein antigens.  
 The prevalence of the various Group B capsular serotypes varies over 
time and may differ from place to place. Prior to the 1990s, most Group B 
Streptococcal disease was caused by serotypes Ia, Ib, II, III, and V; serotypes 
IV and VI through VIII were relatively uncommon. During the early to mid-
1990s, serotype V stains began to emerge, with the percentage of isolates in this 
group increasing from 2.6% in 1992 to 20% in 1994 90,91.  Studies conducted in 
the U.S. and abroad indicate that serotypes Ia, Ib, II, III and V now predominate 
among vaginal isolates and clinical isolates from patients 92,94,94. Recently, 
serotypes VI and VII have appeared as the predominant serotypes in Japan 95.  
 Neonatal early-onset disease due to serotype VIII has also been reported 
in Japan 96. Type II strains of GBS account for 60% of isolates from cases of 
neonates sepsis and over 80% of isolates from infants with meningitis, 
suggesting that this GBS serotype possesses enhanced virulence 97. The type  III 
capsular polysaccharide is composed of a repeating structural backbone 
consisting of galactose, glucose, and N-acetyl-neuraminic acid (sialic acid). The 
presence of this molecule on the surface of the organism inhibits activation of 
  
the alternative complement cascade and prevents phagocytosis. Removal of 
sialic acid residues with neuraminidase leads to complement activation 
phagocytosis, and intracellular killing of the organisms and diminished 
virulence on intravenous challenge in a rat model 98,99.      
 GBS also produce a variety of other potential virulence determinants. 
Like the Group A Streptococci,GBS also produce C5a peptidase. C5a is a 
complement component cleavage product that is produced by alveolar epithelial 
cells, acts as an attractant for inflammatory cells, and is involved in the process 
of pulmonary inflammation 100. The C5a peptidase produced by the Streptococci 
cleaves C5a at the C-terminus, thereby interfering with C5-mediated neutrophil 
chemotaxis 101. New information indicates that this peptidase also binds to 
fibronectin  102.  
Group B β-hemolytic Streptococci are a major cause of disease in the 
neonatal and perinatal periods. Women become colonize with the organism in 
the vagina and the rectum, and vaginal colonization is found in 10-35% of 
pregnant women; up to 60% of the colonized women will carry the organism 
intermittently 103,104. Colonization of the vagina may actively reflect 
contamination from the rectum, with the gastrointestinal tract being the 
principal reservoir of the organism.  
 
  
COMPLICATIONS 
GBS is associated with a spectrum of maternal and fetal infections 
ranging from asymptomatic colonization to sepsis. Streptococcus agalactiae has 
been implicated in adverse pregnancy out comes, including preterm labor, 
prematurely ruptured membranes, clinical and subclinical chorioamnionitis, and 
fetal and neonatal infections. It is associated with about 20% of postpartum 
endometritis, 25% of bactremias following caesarean section, and 25-30% of 
cases of asymptomatic bacteriuria during and after pregnancy, they are also 
associated with a variety of infections in nonpregnant adults 105. 
 
NEONATAL INFECTIONS 
Early-Onset disease occurs with an incidence of 0.7 in 1.000 to 3.7 in 
1,000 live births and is associated with in utero or perinatal organism 
acquisition 106. The organism is acquired either by ascending infection in utero 
before delivery, through ruptured fetal membranes, or during passage through a 
birth canal that is colonized with GBS. Although a substantial proportion of 
these infants (approximately 50%) will be colonized with GBS, only 1-2% of 
them become infected 107. Onset of disease occurs during the first 5 days of life; 
in more than half the cases, infants become ill within the first 12 to 20 hours 
after birth 108. The disease spectrum includes bacteremia, pneumonia, 
  
meningitias, septic shock, and neutropenia. Although more than 50% of cases 
occur in full-term infants, a higher attack rate and greater morbidity are 
associated with preterm infants. Mortality owing to early – onset disease in full-
term infants ranges from 2% to 8%; higher mortality rates are seen in premature 
infants and are inversely proportional to the birth weight of the neonate 109. 
Maternal factors that increase the risk for early –onset infection of the neonate 
include premature labour, prolonged rupture of the fetal membranes, 
postpartum bacteremia, maternal amnionitis, heavy vaginal colonization with 
Group B Streptococci, and Group B Streptococci bacteriuria 110,111.  
Late –onset disease occurs with an incidence of 0.5 in 1,000 to 1.8 in 
1,000 live births 98. Disease becomes clinically evident 7 days to 3 months 
(average, 3 to 4 weeks) after birth. Whereas about half of the late –onset 
infections are acquired from the birth canal of colonized mothers, the remaining 
cases result from postnatal organism acquisition from the mother or other 
caregivers or nosocomially 112. Bacteremia with accompanying meningitis is the 
predominant clinical presentation 113. Mortality associated with late-onset 
disease is about 10-15%. Up to 50% of children with late onset meningitis will 
have permanent neurologic complications and sequelae 114. The distribution of 
Group B Streptococci serotypes also varies according to whether it is early- 
onset disease without meningitis, the serotype distribution is equally divided 
  
among types Ic, II, and III. Among similarly infected neonates with meningitis, 
serotype III strains account for over 90% of the isolates. On the other hand, 
group B streptococcal meningitis in adults is associated primarily with serotype 
II organisms.  
 With the decline in neonatal Group B Streptococcal disease, over two-
thirds of infections in adults are not associated with pregnancy. Adults with 
group B disease usually have significant underlying disease, including diabetes, 
liver cirrhosis, stroke, neoplasia, or urinary tract dysfunction 115. Skin and soft-
tissue infections are the most common clinical entities associated with invasive 
Group B Streptococci and include cellutitis, abscesses, infected decubitus 
ulcers, and invasive would infections following surgical procedures 116. 
Ostemyelitis may occur as a complication of cellulites by contiguous spread, 
particularly in association with decubitus ulcers, or as a result of hematogenous 
seeding from another site of infection. Group B streptococci are also the major 
cause of osteomyelitis in infants, with hematogenous seeding of bone being the 
source of the organism.  
 Bacteruria with Group B Streptococci has been associated with adverse 
pregnancy outcome, increased rates of premature labor, and premature rupture 
of fetal membranes. Besides being a well-recognized cause of urinary tract 
infection in pregnant women, this organism is also a cause of cystitis and 
  
pyelonephritis in men, nonpregnant women, and children. Anywhere from 5% 
to over 20% of nonpregnant adults with bacteremia will have Group B 
streptococcal urinary tract infection 117. Risk factors for urinary tract infection 
caused by Group B Streptococci include advanced age, underlying disease 
(especially diabetes) , presence of an indwelling urinary catheter, prior urinary 
tract infections, structural abnormalities of the urinary. Pyelonephritis and renal 
abscess are potential complications of both ascending infection and 
hematogenous dissemination of Group B Streptococci 118.  
By the mid-1980s, increased knowledge regarding group B Streptococci 
infections and the recognition of the symptoms in at-risk patients led to 
improvements in neonatal care that resulted in reduction of the fatality rate to 
about 15%. Since infants born to heavily colonized mothers are more likely to 
have early-onset disease and because infants who acquire a large bacterial 
inoculum during birth have significantly increased likelihoods of having both 
early-and late- onset disease, the identification of colonized mothers became a 
central focus for prevention strategies. Investigators examined possible 
interventions to prevent GBS disease, and several clinical trials demonstrated 
that intrapartum administration of antimicrobial agents interrupted the 
transmission of GBSi from the mother to the neonate and reduced the incidence 
of early-onset infections 119,120,121. This chemoprophylactic approach prevented 
  
about 70 -75% of early-onset disease, but it had no effect on the development of 
late-onset disease.  Several manufactures of microbiology products started to 
develop direct detection methods for Group B Streptococci in vaginal swab 
specimens similar to those used for direct detection of Group A Streptococci in 
throat swab specimens. These tests used anti- Group B Streptococci antibodies 
to detect organisms directly by latex agglutination or rapid visual or colormetric 
immunoassay formats. Theoretically, these rapid test could be performed in the 
immediate prepartum period to determine colonization status, and antimicrobial 
chemoprophylaxis could be administered prior to and during delivery if the 
antepartum assays were positive. These commercial rapid tests for direct 
detection of Group B Streptococci in vaginal swab specimens varied 
significantly in sensitivity (i.e., 11-88%) when compared with overnight broth 
techniques and, in general, identified only women who were heavily colonized 
122, 123,124. 
 
RECOMMENDED PREVENTION STRATEGIES 
 In 1996, the Centers for Disease Control and Prevention (CDC), together 
with the American Academy of Pediatrics (AAP) and the American College of 
Obstetrics and Gynecology (ACOG) issued consensus recommendations on a 
prevention strategy for Group B Streptococcal disease 125,126,127.       
  
 These guidelines recommended that obstetrical healthcare providers 
adopt either a culture –based or a risk-based strategy for the prevention of early-
onset Group B Streptococcal disease. A critical component of these guidelines 
is the use of maternal antimicrobial prophylaxis during labor and delivery. To 
date, no penicillin-resistant strains of Group B Streptococci have been isolated, 
although clindamycin and erythromycin resistance has become relatively 
common.  
 In 2002, the Committee on Obstetrical Practice issued a statement 
supporting the use of culture-based prevention strategies based on data from the 
Active Bacterial Core Surveillance Emerging Infections Program network 
suggesting that the culture-based approach was superior to the risk-based 
approach 129. New guidelines were issued by the CDC in 2002, replacing the 
1996 guidelines and recommending universal, pre-natal, culture-based 
screening for vaginal and rectal colonization of all pregnant women at 35-37 
weeks of gestation. 
 
  
 
 
 
 
 
 
 
         
 
 
 
 
 
 
 
 
 
 
 
CDC GUIDELINES FOR GROUP B STREPTOCOCCUS PROPHYLAXIS 
 
Vaginal and rectal GBS screening cultures at 35-37weeks’ gestation for ALL pregnant women 
(unless patient had GBS bacteriuria during the current pregnancy or a previous or a infant with 
invasive GBS disease 
Intrapartum prophylaxis indicated  
 
● Previous infant with GBSdisease 
● GBS bacteriuria during current pregnancy  
● Positive GBS screening culture during 
current pregnancy (Unless a planned 
cesarean delivery. In the absence of labour 
or amniotic membrane rupture, is 
performed.) 
● Unknown GBS status (culture not done, 
incomplete, or results unknown) and any of 
the following: 
● Delivery at <37 weeks’ gestation  
● Amniotic membrane rupture  ≥ 18 hours  
● Intapartum temperature ≥ 100.40F  . 
 
 
Intrapartum prophylaxis not indicated  
 
1. Previous pregnancy with a 
positive GBS screening culture 
(unless a culture was also positive 
during the current pregnancy) 
2. Planned cesarean delivery 
performed in the absence of labor 
or membrane rupture (regardless 
of maternal GBS culture status) 
3. Negative vaginal and rectal GBS 
screening culture in late gestation 
during the current pregnancy, 
regardless of intrapartum risk 
factors  
 
 
 
 
 
 
 
 
 
 
      
 
 
    GBS 
 
        Positive  
 
 
 
No growth at 48 hours 
 
 
 
 
 
 
 
CDC GUIDELINES FOR GROUP B STREPTOCOCCUS PROPHYLAXIS (CONT'D)
Onset of labor or rupture of membranes at < 37 weeks’ gestation with significant risk for imminent preterm delivery  
NO GBS culture GBS positive GBS negative 
Obtain vaginal and 
rectal GBS culture 
and initials IV 
antimicrobials  
antimicrobials
 
IV antimicrobials 
for ≥ 48 hours 
(during tocolysis)  
No GBS 
prophylaxis  
Stop antimicrobials  
Intrapartum 
antimicrobial 
prophylaxis at 
delivery   
In our study one Swab taken from a neonate was found to be positive for 
Group B Streptococci. The mother of this neonate was also positive by 
vaginal swab for GBS, the pregnancy was associated with Premature 
Rupture of Membranes and the neonate was diagnosed with neonatal sepsis. 
After treatment, the neonate made a full recovery.  
 
 It was also found that the incidence of Preterm Labour in those 
mothers who were positive for GBS was 25.0%; compared to 3.5% in those 
mothers who were negative for GBS.  
 Similarly, the incidence of Premature Rupture of Membranes in those 
mothers who were positive for GBS was 25.0%; compared to 10.2% in those 
mothers who were negative for GBS.  
 
 Like the Group A streptococci, isolates of GBS remain suseptiple to 
penicillin G, the drug of choice for treatment of infections and for perinatal 
chemoprophylaxis of women who are vaginal carriers of Group B 
streptococci. Ampicillin, cefotaxime, cefotaxone, cefezolin, and meropenem 
are also highly active. Some GBS demonstrate resistance to erythromycin 
and clindamycin.  
 
 In our study GBS was sensitive to Penicillin, Vancomycin, 
Erythromycin , Ciprofloxacin and Tetracyclin, but was resistant to 
Gentamycin and Amikacin . 
 
 The incidence of Neonatal Sepsis in neonates born to those mothers 
who were positive for GBS was 20.0%; compared to 1.5% in those mothers 
who were negative for GBS. This indicates a maternal to fetal transmission 
rate of 20.0% which is less than the 50 % maternal to fetal transmission rate 
reported in other studies.  
 
 These results indicate that there is a definitive increased risk of 
Pre-term Labour, Premature rupture of Membranes and Neonatal Sepsis in 
pregnant women who are colonized with GBS. 
CONCLUSIONS 
 Group B Streptococcus colonization in the pregnant mother has been 
associated with a number of maternal and neonatal complications. 
These include higher rates of Premature Rupture of Membranes, 
Premature Delivery, Puerperal Infection, and Neonatal Sepsis.  
 
In our study we have attempted to determine the prevalence of 
colonization of Group B Streptococci in mothers at the time of 
admission to the Labour Room and in neonates soon after delivery. The 
study patients were then followed up in order to detect any association 
with maternal and nonatal complications. Our study excluded 
Caesarean deliveries. 
 
In our study, the prevalence of Group B Streptococci in the 
Maternal samples was found to be 2.0%. The incidence of Preterm 
Labour in those mothers who were positive for Group B Streptococcus 
was 25.0%; compared to 3.5% in those mothers who were negative for  
Group B Streptococcus.  
 
Similarly, the incidence of Premature Rupture of Membranes in those 
mothers who were positive for Group B Streptococcus was 25.0%; 
compared to 10.2% in those mothers who were negative for Group B 
Streptococcus.  
 
 The incidence of Neonatal Sepsis in neonates born to those 
mothers who were positive for Group B Streptococcus was 20.0%; 
compared to 1.5% in those mothers who were negative for  Group B 
Streptococcus.  
 
These results indicate that there is a definite increased risk of Pre-
term Labour, Premature rupture of Membranes and Neonatal Sepsis in 
pregnant women who are colonized with Group B Streptococcus.  
 
It was also found that the samples of  Group B Streptococci 
obtained in our study was sensitive to 
Vancomycin,Erythromycin,Penicillin,Ciprofloxacin and tetracycline 
and showed resistance to Amikacin and Gentamycin. 
 
The prevalence of maternal colonization with Group B 
Streptococci in our study population is low at only 2 %, which is 
comparable with other studies conducted in India (1.3 – 2.5 %). But the 
reported prevalence in Western countries is higher ranging from 6.4 – 
35 %. The association of pre-term labour, pre-mature rupture of 
membranes and neonatal sepsis was found significant in pregnant 
women who were colonized with Group B Streptococci. As the 
prevalence of Group B Streptococci is low, it is not cost effective to do 
a culture based screening at 37 weeks of gestation for all pregnant 
women as per ACOG and CDC guidelines. 
 
The low occurrence of Group B Streptococci maternal 
colonization (2%) and neonatal transmission (0.5 %) shows that 
selective risk factor based screening and anti-biotic prophylaxis should 
be considered as an effective protocol for preventing neonatal 
morbidity and mortality due to Group B Streptococci than a mass 
screening for Group B Streptococci during pregnancy. 
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PROFORMA  
 
NAME :      ADDRESS : 
AGE : 
PARITY :     SOCIO ECONOMIC STATUS: 
GESTATIONAL AGE AT ONSET OF LABOUR :  
OBSTETRIC HISTORY : 
 
 
PAST HISTORY : 
 
 
FAMILY HISTORY: 
 
DETAILS OF PRESENT PREGNANCY : 
 
 
 
UTI IN CURRENT PREGNANCY : 
GENERAL EXAMINATION: 
 
VAGINAL EXAMINATION FINDINGS : 
 
SWAB : VAGINAL INTROITUS TO ANUS : 
 
 
TIME OF RUPTURE OF MEMBRANES :  
DURATION OF LABOUR :  
 
MADE OF DELIVERY :  
 
 
SEX :  
 
WEIGHT OF BABY : 
 
REPORT OF VAGINAL SWAB CULTURE :  
SWABS FROM NEONATE :  
 
 SITES      REPORTS  
 
1) NASAL SWAB  
2) THROAT SWAB  
3) UMBILICAL SWAB  
4) EXTERNAL EAR SWAB  
 
POST PARTTUM COMPLICATIONS: 
 
1) FEVER  
2) UTI  
3) FOUR SMELLING LOCHIA   
 
* * *  
 
S.No 
IP 
Number age 
obstetrical 
score 
Socio 
economic 
class 
GA at 
onset of 
labour PROM 
Sex of 
Baby 
Weight 
of Baby 
Report swab for 
GBS 
Post Partum 
Complications 
 
      
Primigravida 
Multigravida  
  
        Maternal Neonatal Fever UTI 
Lochia 
foul 
smelling 
1 704279 34 M  II  Term  -  M  3.5  -  -  -  -  - 
2 704264 25 P  III  Term  -  F  3  -  -  -  -  - 
3 702361 21 P  IV  Term  -  M  2.4  -  -  -  -  - 
4 702843 24 M  III  Term  -  F  2.75  -  -  -  -  - 
5 712803 31 M  V  Term  -  M  2.65  -  -  -  -  - 
6 703108 26 P  V  Term  -  M  2.75  +  -  -  -  - 
7 703430 21 M  III  Term  -  F  2.8  -  -  -  -  - 
8 703545 22 P  V  36  +  M  2.3  -  -  -  -  - 
9 703378 18 P  I  Term  -  F  3.15  -  -  -  -  - 
10 703378 24 M  IV  Term  -  M  3  -  -  -  -  - 
11 703782 23 P  V  Term  -  F  2.65  -  -  -  -  - 
12 703962 23 M  III  Term  -  M  2.95  -  -  -  -  - 
13 704240 27 P  V  Term  -  F 2.5   -  -  -  -  - 
14 704149 24 M  IV  Term  -  M  2.7  -  -  -  -  - 
15 704433 23 P  II  Term  -  M  2.8  -  -  -  -  - 
16 704450 32 P  V  Term  -  F  3.75  -  -  -  -  - 
17 704533 21 M  III  Term  +  M  2.8  -  -  -  -  - 
18 703632 17 P  V  Term  -  M  2.9  -  -  -  -  - 
19 702985 23 M  II  Term  - F   2.8  -  -  -  -  - 
20 703025 28 P  IV  Term  -  M  2.45  -  -  -  +  - 
21 703169 25 P  III  Term  -  M  2.6  -  -  -  -  - 
22 704609 22 M  V  35  -  F 2.45   -  -  -  -  - 
23 704722 31 P  IV  Term  -  M  2.8  -  -  -  -  - 
24 704870 24 P  II  Term  -  F 2.3   -  -  -  -  - 
25 704671 23 M  V  Term  +  M  2.8  -  -  -  -  - 
26 704652 27 M  IV  Term -   F  2.8  -  -  -  -  - 
27 704772 28 P  II  Term  -  M  3.55  -  -  -  -  - 
28 704789 22 P  V  Term  -  F  3.4  -  -  -  -  - 
29 704670 21 M  V  Term  -  M  3.1  -  -  -  -  - 
30 704897 23 P  III  Term  -  F  3.2  -  -  -  -  - 
31 704924 18 P  IV  Term  +  M  2.3  -  -  -  -  - 
32 704988 21 M  II  Term  -  M  3.1  -  -  -  -  - 
33 705171 25 P  IV  Term  -  F  3  -  -  -  +  - 
34 705199 21 M  III  36  -  M  2.5  -  -  -  -  - 
35 705362 32 P  IV  Term  -  F  2.8  -  -  -  -  - 
36 705395 22 P  III  Term  -  M  2.75  -  -  -  -  - 
37 705180 24 M  II  Term  +  M  2.65  -  -  -  -  - 
38 705047 23 M  V  Term  -  M  2.5  -  -  -  -  - 
39 704714 30 P  V  Term  -  M  3.6  -  -  -  -  - 
40 701026 24 P  V  Term  -  M  2.8  -  -  -  -  - 
41 704517 31 M  V  Term  -  F  3.1  -  -  -  -  - 
42 5017135 27 P II   Term  -  M  3  -  -  -  -  - 
43 603550 18 P  V  Term  -  F  2.9  -  -  -  -  - 
44 603283 23 M III  Term  -  M 2.4   -  -  -  -  - 
45 603092 25 P IV   Term  -  M  2.95  -  -  -  -  - 
46 602731 28 M IV  Term  -  F  2.9  -  -  -  -  - 
47 602524 29 P  V  Term  -  M  2.9  -  -  -  -  - 
48 601821 24 P  III  Term  -  M  2.7  -  -  -  -  - 
49 601832 23 M  IV  Term  -  F  2.3  -  -  -  -  - 
50 601569 32 P  V  Term  +  M  2.8  -  -  -  -  - 
51 601444 25 P  IV  Term  -  F  3  -  -  -  -  - 
52 601589 26 M  V  Term  -  M  3.2  -  -  -  +  - 
53 601376 24 M  V  Term  -  F  3.2  -  -  -  -  - 
54 600963 23 P  III  Term  -  M  3.1  -  -  -  -  - 
55 601027 21 P  V  Term -   F  3  -  -  -  -  - 
56 600725 18 M  IV  Term -  M  3  -  -  -  -  - 
57 601024 30 P  II  32 -  M 2.25   -  -  -  -  - 
58 600877 21 M  III  Term -  F  3.2  -  -  -  -  - 
59 600740 23 P  IV  Term -  F  3.15  -  -  -  -  - 
60 600705 23 P  IV  Term -  M  2.85  -  -  -  -  - 
61 600594 19 M  I  Term -  F  2.65  -  -  -  -  - 
62 600880 26 M  III  Term -  M  2.8  -  -  -  -  - 
63 600828 25 M  IV  Term -  F  2.9  -  -  -  -  - 
64 600741 33 P  V  Term -  M 3.2   -  -  -  -  - 
65 600468 24 P  IV  Term  +  M  2.25  -  -  -  +  - 
66 600566 25 M  V  Term -  F  3  -  -  -  -  - 
67 600204 24 M  III  Term -  M  2.8  -  -  -  -  - 
68 603456 31 P  IV  Term -  F  3.2  -  -  -  -  - 
69 502324 26 P  II  Term -  M  3  -  -  -  -  - 
70 502331 23 M  III  Term -  M  3.1  -  -  -  -  - 
71 503211 25 P  V  Term -  M  3.1  -  -  -  -  - 
72 502297 31 P  III  Term -  F 2.5   -  -  -  -  - 
73 502298 27 M  V  Term +  M  3.2  -  -  -  -  - 
74 502281 24 P  II  Term -  M  3.1  -  -  -  -  - 
75 502274 23 P  IV  Term -  F  3  -  -  -  -  - 
76 502201 26 P  V  35 -  M  2.4  +  -  -  -  + 
77 502160 25 M  III  Term -  F  3.2  -  -  -  -  - 
78 502147 26 P  IV  Term -  M  3  -  -  -  -  - 
79 502080 24 M  V  Term -  F  3.1  -  -  -  -  - 
80 502026 23 P  V  Term -  M  3  -  -  -  -  - 
81 501992 30 M  IV  Term -  F  2.2  -  -  -  -  - 
82 501992 25 P  II  Term -  F  2.45  -  -  -  +  - 
83 501965 23 P  V  Term -  M  2.7  -  -  -  -  - 
84 501949 17 P  V  Term -  F  2.8  -  -  -  -  - 
85 501871 22 P  IV  Term -  M  2.9  -  -  -  -  - 
86 501877 21 M  III  Term  -  F  3.2  -  -  -  -  - 
87 501873 22 M  V  Term  +  M  3  -  -  -  -  - 
88 501774 23 P  IV  Term  -  F  3.1  -  -  -  -  - 
89 501878 23 P  III  Term  -  M 2.3   -  -  -  -  - 
90 501763 35 P  V  Term  -  F  3  -  -  -  -  - 
91 501747 25 M  II  Term  -  M  2.9  -  -  -  -  - 
92 501749 24 M  III  Term  -  F  2.8  -  -  -  -  - 
93 501744 23 P  V  Term  -  F  2.3  -  -  -  -  - 
94 501750 23 M  IV  Term  -  F  2.8  -  -  -  -  - 
95 502005 24 P  V  Term  -  M  3.2  -  -  -  -  - 
96 701452 21 M  III  Term  -  M  2.4  -  -  -  +  - 
97 603616 32 P  V  Term  -  F  3.1  -  -  -  -  - 
98 601605 23 P  II  Term  -  M  3  -  -  -  -  - 
99 601199 24 M  V  Term  -  F  2.9  -  -  -  -  - 
100 601121 25 P  V  Term  -  M  2.5  -  -  -  -  - 
101 601302 24 M  II  Term  -  F  2.8  -  -  -  -  - 
102 601122 24 P  IV  Term  -  M  2.8  -  -  -  -  - 
103 608704 32 M  III  Term  +  M 2.4   -  -  -  -  - 
104 608444 25 P  IV  Term  -  M  3  -  -  -  -  - 
105 608380 24 M  V  Term  -  F  2.9  -  -  -  -  - 
106 607762 25 M  III  Term  -  M 2.4   -  -  -  -  - 
107 609826 23 M  IV  Term  -  F  3.2  -  -  -  -  - 
108 601247 32 P  V  Term  - M   3  -  -  -  -  - 
109 601277 24 M  III  Term  -  F  3.1  -  -  -  -  - 
110 601266 25 M  IV  Term  -  M  2.5  -  -  -  -  - 
111 706372 17 P  V  Term  -  F  3  -  -  -  -  - 
112 706434 24 M  V  Term  -  M  2.7  -  -  -  -  - 
113 702627 26 P  IV  Term  +  F  2.9  -  -  -  +  - 
114 703131 27 M  II  Term  -  M  2.8  -  -  -  -  - 
115 703179 24 P  V  Term  -  M  3  -  -  -  -  - 
116 703417 25 M  V  Term  -  F  3.2  -  -  -  -  - 
117 703726 21 P  IV  Term  -  M  3.1  -  -  -  -  - 
118 704149 23 M  V  Term  -  F  3.  -  -  -  -  - 
119 702361 34 P  III  Term  -  M  2.4  -  -  -  -  - 
120 704264 22 M  IV  Term  -  M  3  -  -  -  -  - 
121 704279 22 P  V  Term  +  F  3.2  -  -  -  -  - 
122 702354 23 M V Term - M 3 - - - - - 
123 704517 21 M  III  Term  -  M  3.2  -  -  -  -  - 
124 706581 23 M  V  Term  -  F  3.1  -  -  -  -  - 
125 706373 24 p  IV  Term  -  M  3  -  -  -  -  - 
126 706621 23 P  V  Term  -  M  2.8  -  -  -  -  - 
127 701440 19 M  II  Term  -  F  2.5  -  -  -  -  - 
128 706732 25 P  IV  Term  -  M  3.1  -  -  -  -  - 
129 706741 25 M  V  Term  -  F  3.3  -  -  -  -  - 
130 706728 36 P  V  Term  -  M  3.1  -  -  -  -  - 
131 706708 27 M  V  Term  -  F  3  -  -  -  -  - 
132 705593 23 M  IV  Term  +  M  2.9  -  -  -  -  - 
133 705748 21 M  V  Term  -  M  2.8  -  -  -  -  - 
134 705878 22 P  V  Term  +  M  2.5  -  -  -  -  - 
135 705967 22 M  IV  Term  -  F  2.8  -  -  -  -  - 
136 705897 21 P  V  Term  -  M  3  -  -  -  -  - 
137 706038 22 M  V  Term  -  M  3.2  -  -  -  -  - 
138 706134 31 M  V  Term  -  M  3.21  -  -  -  -  - 
139 706181 24 M  IV  Term  -  M  3.1  -  -  -  -  - 
140 705670 24 P  II  Term  +  F  3  -  -  -  -  - 
141 706320 23 M  V  Term  -  M  3  -  -  -  -  - 
142 706262 25 P  IV  Term  -  M  2.8  -  -  -  -  - 
143 706578 26 M  V  Term  -  M  2.2  -  -  -  -  - 
144 706502 24 M  II  Term  -  F  2.9  -  -  -  -  - 
145 705243 25 P  V  Term  -  F 2.8   -  -  -  -  - 
146 705573 23 M  IV  Term  -  M  3.6  -  -  -  -  - 
147 705684 24 P  V  Term  -  M  3  -  -  -  -  - 
148 705685 24 M  IV  Term  -  F  2.7  -  -  -  -  - 
149 705678 25 P  V  Term  -  F  3.2  +  -  -  -  - 
150 705859 21 P  V  Term  -  F  2.8  -  -  -  -  - 
151 705569 21 M  IV  Term  -  M  3  -  -  -  -  - 
152 705859 19 M  V  Term  -  F  2.9  -  -  -  -  - 
153 705569 23 P  II  Term  -  M  2.8  -  -  -  -  - 
154 706124 23 P  II  Term  -  F  2.7  -  -  -  -  - 
155 706126 24 P  V  Term  -  M  3  -  -  -  -  - 
156 706372 24 M  IV  36  +  M  2.4  -  -  -  -  - 
157 707209 23 M  V  Term  -  F  2.9  -  -  -  -  - 
158 707326 25 P  IV  Term  -  M  2.7  -  -  -  -  - 
159 707293 26 M  V  Term  -  F  3  -  -  -  -  - 
160 707343 24 P  V  Term  -  M  2.8  -  -  -  -  - 
161 701561 33 M  II  Term  +  F  2.9  -  -  -  -  - 
162 707295 21 P  V  Term  -  M  2.75  -  -  -  -  - 
163 707432 23 M  IV  Term  -  F  2.8  -  -  -  -  - 
164 707449 24 M  V  Term  -  M  3.2  -  -  -  -  - 
165 707496 25 P  V  Term  -  F  3.75  -  -  -  -  - 
166 707468 26 M  IV  Term  -  M  3  -  -  -  -  - 
167 707538 18 M  V  Term  -  F  3.2  -  -  -  -  - 
168 707388 35 P  II   Term  -  M  3.1  -  -  -  -  - 
169 707719 21 M  IV  Term  -  F  3  -  -  -  -  - 
170 707812 22 M  V  Term  -  M  2.9  -  -  -  -  - 
171 706794 22 M  IV  Term  -  M  2.8  -  -  -  -  - 
172 707036 33 M  II  Term  -  F  2.5  -  -  -  -  - 
173 706994 24 P  V  Term  +  M  2.4  -  -  -  -  - 
174 706839 21 P  IV  Term  -  F  2.9  -  -  -  -  - 
175 706988 23 M  IV  Term  -  M  2.8  -  -  -  -  - 
176 706989 25 P  V  Term  -  F  3  -  -  -  -  - 
177 706507 26 M  IV  Term  -  F  3  -  -  -  -  - 
178 708714 28 P  V  Term  +  M  2.7  +  -  -  -  - 
179 708573 17 M  V  Term  -  F  3.1  -  -  -  -  - 
180 708551 26 P  II  Term  -  F  3  -  -  -  -  - 
181 708531 28 M  IV  Term  -  M  2.4  -  -  -  -  - 
182 707928 21 P  V  Term  -  F  2.6  -  -  -  -  - 
183 708238 32 M  IV  Term  -  F  2.9  -  -  -  -  - 
184 708206 23 P  V  Term  -  M  2.8  -  -  -  -  - 
185 708082 24 M  II  Term  -  F  2.9  -  -  -  -  - 
186 707928 25 P  IV  Term  -  F  2.8  -  -  -  -  - 
187 707926 21 P  V  Term  -  M  2.7  -  -  -  -  - 
188 708168 22 M  V  Term  -  F  2.8  -  -  -  -  - 
189 707782 30 P  IV  36  -  M  2.5  -  -  -  +  - 
190 707884 24 M  V  Term  -  F  3  -  -  -  -  - 
191 707977 21 M  IV  Term  -  F  3.1  -  -  -  -  - 
192 707539 21 P  V  Term  +  F  3.1  -  -  -  -  - 
193 707790 23 P  V  Term -   F  3  -  -  -  -  - 
194 707849 31 P  II  Term -   F  2.6  -  -  -  -  - 
195 707795 26 M  V  Term -   F  2.9  -  -  -  -  - 
196 707641 23 P  IV  Term -   F  2.6  -  -  -  -  - 
197 777650 25 M  IV  Term -   F  2.7  -  -  -  -  - 
198 707624 24 P  V  Term -   F  3.2  -  -  -  -  - 
199 707705 21 M  V  Term -   M  2.45  -  -  -  -  - 
200 707705 20 P  V  Term -   F  3  -  -  -  -  - 
 
